[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557476":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":51,"collaborators":54,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":19,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":19,"enrollmentInfo":71,"targetDuration":19,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Auckland, New Zealand","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Holter monitor","EXPERIMENTAL","Holter monitor for 48 hours",[13],"Device: Holter monitor",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3).\n\nHolter monitor to be worn for approximately 46-48 hours.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Jade Scott","CONTACT","+64 (0)9 923 4222","j.scott@auckland.ac.nz",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Sarah Benge","+64276045647","s.benge@auckland.ac.nz",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Auckland City Hospital","RECRUITING","Auckland","1023","New Zealand","NZ",{"type":39,"coordinates":40},"Point",[41,42],174.76349,-36.84853,{"lat":42,"lon":41},[45,49],{"name":46,"role":23,"phone":47,"phoneExt":19,"email":48},"Study Coordinator","643074949","researchassistant@adhb.govt.nz",{"name":50,"role":23,"phone":19,"phoneExt":19,"email":19},"Jane So",{"type":52,"investigatorFullName":50,"investigatorTitle":53,"investigatorAffiliation":32,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Principal Investigator",[55,58,60],{"name":56,"class":57},"Gut Cancer Foundation","UNKNOWN",{"name":32,"class":59},"OTHER_GOV",{"name":61,"class":57},"The Heart Group","100557476","the-5-fu-holter-study-100557476",false,"NCT06538610","The 5-FU Holter Study","Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy","Inclusion Criteria:\n\n* Patients with diagnosis of gastrointestinal malignancy\n* Planned to receive either FOLFOX chemotherapy with any treatment intent\n* Aged ≥ 18 years at time of signing informed consent form\n\nExclusion Criteria:\n\n• ECG with left bundle branch block or left ventricular hypertrophy with strain","ALL","18 Years",{"count":72,"type":73},10,"ESTIMATED","INTERVENTIONAL",[76],"NA","To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy",[79],"Gastrointestinal Malignancy","2024-12-04",{"date":82,"type":83},"2024-12-09","ACTUAL",{"date":85,"type":83},"2024-11-01",{"date":87,"type":73},"2026-01",{"name":5,"class":6},1]